Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of a formula for individual dosage of nedaplatin based on renal function

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Nedaplatin (NDP), a platinum derivative, has been developed to reduce nephrotoxicity and gastrointestinal toxicity of cisplatin. The pharmacokinetic profile of NDP is similar to that of carboplatin (CBDCA). The optimal dosing for CBDCA is determined by the area under the curve (AUC) using Calvert’s formula. However, the administration dose of nedaplatin (NDP) is determined based on the body surface area in clinical treatment. Ishibashi et al. reported a formula for predicting NDP clearance based on renal function like Calvert’s formula for CBDCA. We conducted the present study to evaluate the Ishibashi’s formula.

Methods

A total of 22 patients with cervical or ovarian cancer, who underwent chemotherapy consisting of NDP and irinotecan (CPT-11), were examined in this study. Blood samples were collected at 0, 1, 2, 4, and 6 h after the end of infusion of NDP (48–80 mg/m2), and free platinum concentrations were measured. Observed AUCs were compared with predicted AUCs, which were calculated by the Ishibashi’s formula. In addition, the relative reduction in platelets (PLTs) was assessed as a parameter of adverse effects.

Results

The observed AUC of NDP ranged from 4 to 14 (μg h−1 ml−1) with large variation. The predicted AUC based on renal function was correlated with the observed AUC. There was a relationship between observed AUC and the decrease in PLTs.

Conclusions

Ishibashi’s formula would be predictable and useful for estimating the individual dose of NDP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Niioka T, Uno T, Yasui-Furukori N, Takahata T, Shimizu M, Sugawara K, Tateishi T (2007) Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma. Cancer Chemother Pharmacol 59:575–580

    Article  PubMed  CAS  Google Scholar 

  2. Koenuma M, Kasai H, Uchida N, Takeda Y, Shiratori O, Muraoka Y, Totani T (1995) Antitumor activity of a new platinum complex, nedaplatin. Clin Rep 29:3213–3222

    Google Scholar 

  3. Weiss RB, Christian MC (1993) New cispaltin analogue in development. Drugs 46:360–377

    Article  PubMed  CAS  Google Scholar 

  4. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) An early phase II clinical study of cis-diammine glycolato platinum, 254-s, for head and neck cancers. Jpn J Cancer Chemother 19:863–869

    CAS  Google Scholar 

  5. Inuyama Y, Hirosato M, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) A late phase II clinical study of cis-diammine glycolato platinum, 254-s, for head and neck cancers. Jpn J Cancer Chemother 19:871–877

    CAS  Google Scholar 

  6. Furuse K, Fukuoka M, Kurita Y, Ariyoshi Y, Niitani H, Yoneda S, Fujii M, Hasegawa K, Nishiwaki Y, Tamura M, Kimura I, Inoue S, Oshima S, Kusume K, Sugimoto K (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for plimary lung cancer. Jpn J Cancer Chemother 19:879–884

    CAS  Google Scholar 

  7. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, Ota K (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. Jpn J Cancer Chemother 19:483–488

    CAS  Google Scholar 

  8. Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, Aso Y (1992) Phase II study of cis-diammine (glycolato) platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S urological cancer. Cancer Chemothe Pharmacol 31:187–192

    Article  CAS  Google Scholar 

  9. Noda K, Ikeda M, Yakushiji M, Nishimura H, Terashima Y, Sasaki H, Hata T, Kuramoto H, Tanaka K, Takahashi T, Hirabayashi K, Yamabe T, Hatae M (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus. Jpn J Cancer Chemother 19:885–892

    CAS  Google Scholar 

  10. Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M, Ohashi Y (2000) Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncol 58:31–37

    Article  CAS  Google Scholar 

  11. Machida S, Ohwada M, Fujiwara H, Konno R, Takano M, Kita T, Kikuchi Y, Komiyama S, Mikami M, Suzuki M (2003) Phase I study of combination chemothearpy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. Oncology 65:102–107

    Article  PubMed  CAS  Google Scholar 

  12. Sugiyama T, Yakushiji M, Kamura T, Ikeda M, Umesaki N, Hasegawa K, Ishikawa M, Saji F, Hiura M, Takahashi T, Sato S, Oshiai K, Kikkawa F, Takeuchi S, Ohashi Y, Noda K, Japan CPT-11Study Group (2003) Irinotecan (CPT-11) and cisplatin as first line chemotherapy for advanced ovarian cancer. Oncology 63:16–22

    Article  Google Scholar 

  13. Matsumura M, Takeshima N, Ota T, Omatsu K, Sakamoto K, Kawamata Y, Umayahara K, Tanaka H, Akiyama F, Takizawa K (2010) Neoadjuvant chemoteharpy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for stage IB2-IIB cervical cancer–Irinotecan and platinum chemotherapy. Gynecol Oncol 119:212–216

    Article  PubMed  Google Scholar 

  14. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756

    PubMed  CAS  Google Scholar 

  15. Chatelut E, Canal P, Brunner V, Chevreau C, Boneu A, Roche H, Houin G, Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573–580

    Article  PubMed  CAS  Google Scholar 

  16. Ota K, Oguma T, Shimamura K (1994) Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine (glycolate) platinum, 254-S. Anticancer Res 14:1383–1388

    PubMed  CAS  Google Scholar 

  17. Sasaki Y, Tamura T, Taguchi K, Shinka T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S, Minato K, Nakagawa K, Saijyo N (1989) Pharmacokinetics of (glycolato-O, O’)-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243–246

    Article  PubMed  CAS  Google Scholar 

  18. Ishibashi T, Yano Y, Oguma T (2002) A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother Pharmacol 50:230–236

    Article  PubMed  CAS  Google Scholar 

  19. Ikeuchi I, Daikatsu K, Fujisawa I, Amano T (1990) Determination of platinum in biological materials by graphic furnace atomic absorption spectorometry. Iyakuhin Kenkyu 21:1082–1087

    CAS  Google Scholar 

  20. Ishibashi T, Yano Y, Oguma T (2003) Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 56:205–213

    Article  PubMed  CAS  Google Scholar 

  21. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503–512

    Article  PubMed  CAS  Google Scholar 

  22. Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimization of carboplatin. Clin Pharmacokinet 33:161–183

    Article  PubMed  CAS  Google Scholar 

  23. Ishibashi T, Yano Y, Oguma T (2005) Determination dosage for nedaplatin based on pharmacokinetic and toxycodynamic analysis. Anticancer Res 25:1273–1282

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None of the authors has any former or present conflict of interest related to this study.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Tottori University, 36-1, Nishi-cho, Yonago City, Tottori, 683 8504, Japan

    Shinya Sato, Tetsuro Oishi, Muneaki Shimada, Hiroaki Itamochi & Junzo Kigawa

  2. Department of Obstetrics and Gynecology, Jichi Medical College, Kawachi-gun, Tochigi, Japan

    Hiroyuki Fujiwara, Shizuo Machida, Yuji Takei & Mitsuaki Suzuki

Authors
  1. Shinya Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyuki Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuro Oishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muneaki Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shizuo Machida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuji Takei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroaki Itamochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mitsuaki Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Junzo Kigawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinya Sato.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sato, S., Fujiwara, H., Oishi, T. et al. Evaluation of a formula for individual dosage of nedaplatin based on renal function. Cancer Chemother Pharmacol 69, 599–603 (2012). https://doi.org/10.1007/s00280-011-1739-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1739-0

Keywords

Search

Navigation